Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial

References

• Parker S L, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5–27
   PubMed Web of Science ®Google Scholar
• Ihde D C. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434–1441
   PubMed Web of Science ®Google Scholar
• Rapp E, Pater J L, William A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer—report of a Canadian Multicenter Randomized Trial. J Clin Oncol 1988; 6: 633–641
   PubMed Web of Science ®Google Scholar
• Woods R L, Williams C J, Levi J, et al. A randomized trial of cis-platin and vindesine versus best supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990; 61: 608–611
   PubMed Web of Science ®Google Scholar
• Thongprasert S, Sanguanmitra P, Umsawasdi T. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) plus chemotherapy. Proc ASCO 1995; 14: 358
   Google Scholar
• Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 794–800
   PubMed Web of Science ®Google Scholar
• Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 1991; 9: 1453–1461
   PubMed Web of Science ®Google Scholar
• Quoix E, Dieteman A, Charbonneau J, et al. Disseminated non-small cell lung cancer: a randomized trial of chemotherapy versus palliative care. Lung Cancer 1988; 4: A181
   Google Scholar
• Kaasa S, Lund E, Thotud E, et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small-cell lung cancer. Cancer 1991; 67: 2443–2447
   PubMed Web of Science ®Google Scholar
• Ganz P A, Figlin R A, Haskell C M, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer Does chemotherapy make a difference?. Cancer 1989; 63: 1271–1278
   PubMed Web of Science ®Google Scholar
• Souquet P J, Chauvin F, Boissel J P, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21
   PubMed Web of Science ®Google Scholar
• Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs. supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861–865
   PubMed Web of Science ®Google Scholar
• Grilli R, Oxman A D, Julian J A. Chemotherapy for advanced nou-small-cell lung cancer: how much benefit is enough?. J Clin Oncol 1993; 11: 1866–1872
   PubMed Web of Science ®Google Scholar
• Stewart L A, Pignon J P, Parmar M KB, et al. A meta-analysis using individual patient data from randomized clinical trials (RCTs) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): survival in the supportive care setting. Proc ASCO 1994; 13: 337
   Google Scholar
• Buccheri G F, Rosso A, Demgno D, et al. Polychemotherapy does prolong the survival of patients with advanced non-small cell lung cancer. A controlled study. XVI World Congress on Diseases of the Chest, Boston, October-November, 30 31989, 118s
   Google Scholar
• Cormier Y, Berneron D, LaForge J, et al. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982; 50: 845–849
   PubMed Web of Science ®Google Scholar
• Ellis P A, Smith I E, Hardy J R, et al. Symptom relief with MVP (mitomycin, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995; 71: 366–370
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Shepherd F A, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter extended phase II study. Eur J Cancer 1996; 32A: 243–248
   PubMed Web of Science ®Google Scholar
• Murphy W K, Winn R J, Huber M, et al. Phase II study of taxol (T) in patients (PT) with non-small cell lung cancer (NSCLC) who have failed platinum (P) containing chemotherapy. Proc ASCO 1994; 13P: 363
   Google Scholar
• Ruckdeschel J, Wagner H, Jr, Williams C, et al. Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): the role of taxol (TAX). Proc ASCO 1994; 13: 357
   Google Scholar
• Grigorescu A. PC (paclitaxel, cisplatin) or MECC (methotrexate, epirubicine, cyclophosphamide, ccnu) as a second-line treatment for non-small cell lung carcinomas (NSCLC). Ann Oncol 1996; 7(Suppl 5)103
   PubMedGoogle Scholar
• Hass C D, Gallardo R L, Moore B, et al. Effective salvage chemotherapy (CT) for relapsed or refractory non-small cell lung cancer (NSCLC) with mitomycin C + paclitaxel + metronidazole (MMC + T + MNZ). Roc ASCO 1996; 15: 391
   Google Scholar
• Chang A Y, Boros L, Garrow A, et al. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 1995; 22(Suppl 6)124–127
   PubMedGoogle Scholar
• Fossella F V, Lee J S, Shin D M, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645–651
   PubMed Web of Science ®Google Scholar
• Robinet G, Thomas P, Perol M, et al. Phase II study of taxotere (docetaxel) (TXT) in advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with platinum. Ann Oncol 1996; 7(Suppl 5)96
   Google Scholar
• Santoro A, Maiorino L, Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 1994; 11(Suppl 1)130
   Google Scholar
• Rinaldi M, Della Giulia M, Venturo I, et al. Vinorelbine (VNB) as a single agent in the treatment of advanced non-small cell lung cancer (NSCLC). Proc ASCO 1994; 13: 360
   Google Scholar
• Kusunoki Y, Furuse K, Yamori S, et al. Randomized phase II study of vinorelbine vs. vindesine in previously untreated non-small cell lung cancer. Lung Cancer 1994; 11(Suppl 1)113
   Google Scholar
• Niitani H, Fukuoka M, Nugao K. Clinical development of ivino-tecan in lung cancers. Lung Cancer 1994; 10(Suppl 2)30–31
   Google Scholar
• Crino L, Mosloni A M, Scaglotti G, et al. Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC). Proc ASCO 1997; 16: 446a
   Google Scholar
• Bonomi P D, Finkelstein D M, Ruckdeschel J C, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602–1613
   PubMed Web of Science ®Google Scholar
• Murphy W K, Fossella F, Winn R J, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384–388
   PubMed Web of Science ®Google Scholar
• Chang A Y, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and prioxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993; 85: 388–394
   PubMed Web of Science ®Google Scholar
• Akerley W, Choy J, Glantz M, et al. Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC). Proc ASCO 1997; 16: 450a
   Google Scholar
• Bonomi P, Kim K, Kugler J, et al. Comparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients treated with etoposide-cisplatin versus taxol-cisplatin: an Eastern Cooperative Oncology Group (ECOG) trial. Proc ASCO 1997; 16: 454a
   Google Scholar
• Arbuck S G. Paclitaxel: What schedule? What dose?. J Clin Oncol 1994; 12: 233–236
   PubMed Web of Science ®Google Scholar
• Georgiadis M S, Russell E, Johnson B E. Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotox-icity. Proc AACR 1994; 35: 341
   Google Scholar
• Wilson W H, Berg S L, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621–1629
   PubMed Web of Science ®Google Scholar
• Seidman A D, Hochauser D, Gollub M, et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study for metastatic breast cancer. J Clin Oncol 1996; 14: 1877–1884
   PubMed Web of Science ®Google Scholar
• Georgiadis M S, Schuler B S, Brown J E, et al. Paclitaxel by 95-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. J Clin Oncol 1997; 15: 735–743
   PubMed Web of Science ®Google Scholar
• Cella D F, Bonomi A E, Lloyd S R, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life Instrument. Lung Cancer 1995; 12: 199–220
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Brisqand D, Douillard J Y, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360–367
   PubMed Web of Science ®Google Scholar
• Murray N, Coppin C, Coldman A, et al. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer. J Clin Oncol 1994; 12: 2333–2339
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Thompson D S, Greco F A. Paclitaxel by I-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13: 1609–1614
   PubMed Web of Science ®Google Scholar
• Fossella F V, Lee J S, Kau S W, et al. Doretaxel (D) for platinum-refractory non-small cell lung cancer (nsclc) and comparison of phase III results to historical controls (HC). Proc ASCO 1997; 16: 468a
   Google Scholar
• Gandara D R, Vokes E, Green M, et al. Docetaxel in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial. Proc ASCO 1997; 16: 454a
   Google Scholar